CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

CytoMed Therapeutics Limited is a Singapore-headquartered pre-clinical biopharmaceutical firm that focuses on creating novel cell-based immunotherapies to combat cancer. Its core pipeline candidate, CTM-N2D, utilizes expanded gamma delta T cells engineered with chimeric antigen receptors targeting natural killer group 2D ligands to drive cytotoxicity against cancer cells. The company is also developing iPSC-gdNKT, which uses induced pluripotent stem cells to produce synthetic hybrid cells combining characteristics of gamma delta T cells and natural killer cells. Additionally, CytoMed is developing CTM-GDT, which employs a multi-recognition system to detect and attack various cancer types.

CytoMed's revenue reached $319,201 in FY2025, rebounding 359.3% after declining 86.3% to $69,501 in FY2024. Revenue was previously $509,125 in FY2023, $365,604 in FY2022, and $84,178 in FY2021, representing a 5-year revenue CAGR of 48.0% from FY2020 to FY2025. Net losses were -$2.1M in FY2021, -$3.1M in FY2022, -$4.1M in FY2023, -$2.5M in FY2024, and -$3.9M in FY2025. Gross margin shifted from 75.4% in FY2024 to -277.7% in FY2025, while R&D expenses climbed to $2.2M in FY2025. For the latest quarter ended June 30, 2026, quarterly revenue fell 15.9% year-over-year, and trailing twelve-month revenue stood at $789,041 with an operating margin of -476.1%.

As of June 30, 2026, CytoMed Therapeutics held $1.5M in cash and short-term investments against total debt of $453,760, resulting in net cash of $1.0M. Total assets stood at $7.0M and shareholders' equity was $5.0M. The company maintains a current ratio of 2.64 and a debt-to-equity ratio of 0.09. Cash burn remains steady, with free cash flow of -$4.4M and operating cash flow of -$3.7M in FY2025. FY2025 capital expenditures were $703,134, while the company's share count increased 62.2% over 5 years.

CytoMed trades at an enterprise value of $9.5M and a market cap of $10.5M. Its price-to-sales multiple is 13.3x, and its EV-to-revenue ratio is 37.3x, both elevated compared to the median of its US-listed Healthcare peers at 4.1x price-to-sales. CytoMed carries a price-to-book multiple of 2.1x. Over the past year, the stock fell 60.9%, trailing the S&P 500 benchmark return of 16.8%. Year-to-date, the stock has declined 34.1% and trades 11.8% below its 200-day moving average.

Wall Street coverage includes 1 Strong Buy rating, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $4.16, representing a potential upside of 372.7% above the last close of $0.88 on October 16, 2026. For the next fiscal year, consensus estimates forecast $0 in revenue and an EPS of $0.00. Over the last 4 quarters, CytoMed posted 1 EPS beat.

This page is an AI-written research summary of CytoMed Therapeutics Limited (GDTC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GDTC income statement, GDTC balance sheet, GDTC key metrics, GDTC analyst forecast, GDTC chart. See the GDTC stock overview for the latest quote and news.